glioblastoma

[Molecular Therapy] The authors reported that FOSL1, a component of activator protein 1 transcription factor complexes, was a key player in regulating proneural-to-mesenchymal transition.

[Laboratory Investigation] Scientists treated glioblastoma cells with RSL3, a ferroptosis inducer, in vitro cell lines and in vivo subcutaneous and orthotopic animal models.

[Journal of Controlled Release] Scientists found that exosomes from primary brain tumors could upregulate the expression of lipocalin-2 in bEnd.3 brain microvascular endothelial cells

[Nature Reviews Neurology] Investigators discuss the latest developments in local therapy for glioblastoma, focusing on recent preclinical and clinical trials.

[Virginia Tech] Robert Gourdie, a cardiovascular scientist at the Fralin Biomedical Research Institute at Virginia Tech Carilion School of Medicine (VTC), is the first Virginia Tech researcher to receive an Outstanding Investigator Award from the National Institutes of Health (NIH).

[Cancer Research] The authors focus on the role of leucine-rich repeat-containing protein (LRRC15) in cancer, including clinical trials involving LRRC15-targeted therapies, such as the ABBV-085 ADC for patients with LRRC15-positive tumors.